<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02558634</url>
  </required_header>
  <id_info>
    <org_study_id>H15-02535</org_study_id>
    <nct_id>NCT02558634</nct_id>
  </id_info>
  <brief_title>Thalamic Deep Brain Stimulation for Spasmodic Dysphonia- DEBUSSY Trial</brief_title>
  <official_title>Thalamic Deep Brain Stimulation for Spasmodic Dysphonia: A Prospective, Randomized, Double-Blinded, Sham-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Laryngeal Dystonia (LD), also commonly referred to as spasmodic dysphonia, is a neurological
      voice disorder characterized by involuntary dystonic contractions of the laryngeal muscles.
      Current treatments such as botox and voice therapy only provide temporary relief and thus,
      the investigators are exploring new strategies to provide long-term, sustained improvement.

      Deep Brain Stimulation (DBS) is a neurosurgical procedure that involves the implantation of
      electrodes to deliver electrical stimuli to specific brain regions. It is the standard
      surgical treatment for many other movement disorders such as Parkinson's disease, essential
      tremor, and primary dystonia. This trial has been designed to test the hypothesis that DBS
      can improve the vocal dysfunction of LD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Unified Spasmodic Dysphonia Rating Scale (USDRS)</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Double-blinded assessments of spasmodic dysphonia with DBS ON/OFF will be conducted using a standardized spasmodic dysphonia rating scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Voice-Related Quality of Life</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Double-blinded assessments of voice-related quality of life with DBS ON/OFF will be conducted using the Vr-QoL for Spasmodic Dysphonia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse/Safety of DBS Implantation and Stimulation in SD</measure>
    <time_frame>12 months</time_frame>
    <description>Stimulation-induced side effects, intraoperative effects, problems with surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beck's Depression Inventory Scale</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment Scale (MoCA)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Voice-Handicap Index</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Controlled Oral Word Association Test</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Spasmodic Dysphonia</condition>
  <condition>Laryngeal Dystonia</condition>
  <condition>Deep Brain Stimulation</condition>
  <arm_group>
    <arm_group_label>DBS-on</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ventral intermediate Nucleus (VIM) Thalamic DBS on
DBS system includes:
Implantable Pulse Generator (IPG)
DBS Lead
DBS Lead Extension Kit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DBS-off (sham-stimulation)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Ventral intermediate Nucleus (VIM) Thalamic DBS off
DBS system includes:
Implantable Pulse Generator (IPG)
DBS Lead
DBS Lead Extension Kit</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VIM Thalamic Deep Brain Stimulation ON</intervention_name>
    <arm_group_label>DBS-on</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VIM Thalamic Deep Brain Stimulation OFF</intervention_name>
    <arm_group_label>DBS-off (sham-stimulation)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically diagnosed isolated laryngeal dystonia (adductor spasmodic dysphonia)

          -  Able to give informed consent

          -  Patients who fall into the age range of 18-75 years old

          -  Patients with inadequate medical and BTX management of spasmodic dysphonia

        Exclusion Criteria:

          -  Dystonia present in other body parts (i.e- eyes, neck, limbs) in addition to larynx

          -  History of laryngeal denervation surgery for spasmodic dysphonia

          -  History of intracranial pathology (such as multiple sclerosis, tumors, or aneurysms)
             that may account for dystonia or essential tremor.

          -  History or evidence of ongoing psychiatric or neurodegenerative disorders (such as
             Parkinson's disease, Alzheimer's disease).

          -  Incompetent adults or those unable to communicate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher R Honey, MD, DPhil</last_name>
      <phone>604.875.5894</phone>
      <email>chris.honey@telus.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Ludlow CL, Adler CH, Berke GS, Bielamowicz SA, Blitzer A, Bressman SB, Hallett M, Jinnah HA, Juergens U, Martin SB, Perlmutter JS, Sapienza C, Singleton A, Tanner CM, Woodson GE. Research priorities in spasmodic dysphonia. Otolaryngol Head Neck Surg. 2008 Oct;139(4):495-505. doi: 10.1016/j.otohns.2008.05.624. Review.</citation>
    <PMID>18922334</PMID>
  </reference>
  <reference>
    <citation>Simonyan K, Tovar-Moll F, Ostuni J, Hallett M, Kalasinsky VF, Lewin-Smith MR, Rushing EJ, Vortmeyer AO, Ludlow CL. Focal white matter changes in spasmodic dysphonia: a combined diffusion tensor imaging and neuropathological study. Brain. 2008 Feb;131(Pt 2):447-59. Epub 2007 Dec 14.</citation>
    <PMID>18083751</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2015</study_first_submitted>
  <study_first_submitted_qc>September 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2015</study_first_posted>
  <last_update_submitted>January 13, 2017</last_update_submitted>
  <last_update_submitted_qc>January 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Christopher Honey</investigator_full_name>
    <investigator_title>Neurosurgeon, Professor of Surgery (Neurosurgery), Director of Surgical Centre for Movement Disorders</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dysphonia</mesh_term>
    <mesh_term>Hoarseness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

